COSCIENS Biopharma (NASDAQ:CSCI) Trading Up 0.6% – Here’s Why

COSCIENS Biopharma Inc. (NASDAQ:CSCI) shares were up 0.6% on Thursday . The stock traded as high as $3.40 and last traded at $3.37. Approximately 832 shares traded hands during mid-day trading, a decline of 93% from the average daily volume of 11,450 shares. The stock had previously closed at $3.35.

COSCIENS Biopharma Trading Up 0.6%

The firm has a market capitalization of $10.62 million, a PE ratio of -0.58 and a beta of 0.74. The firm has a 50-day moving average of $3.49 and a two-hundred day moving average of $3.10.

COSCIENS Biopharma (NASDAQ:CSCI) last announced its quarterly earnings results on Tuesday, May 13th. The company reported ($1.16) earnings per share (EPS) for the quarter. COSCIENS Biopharma had a negative net margin of 194.50% and a negative return on equity of 101.01%. The company had revenue of $1.50 million during the quarter.

About COSCIENS Biopharma

COSCIENS Biopharma Inc, a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests in Canada, Switzerland, Ireland, Denmark, Germany, the United States, and internationally. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of patients with adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as endocrinology and oncology indications; AEZS-150, a delayed clearance parathyroid hormone fusion polypeptide that is in preclinical trial for the treatment of chronic hypoparathyroidism; and AEZS-130 that is in preclinical trial for the treatment of amyotrophic lateral sclerosis.